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Background: Bilirubin can prevent lipid oxidation in vitro, but the association in vivo with oxidized low-density
lipoprotein (Ox-LDL) levels has been poorly explored. Our aim is to the association of Ox-LDL with total bilirubin
(TB) levels and with variables related with metabolic syndrome and inflammation, in young obese individuals.
Findings: 125 obese patients (13.4 years; 53.6% females) were studied. TB, lipid profile including Ox-LDL, markers of
glucose metabolism, and levels of C-reactive protein (CRP) and adiponectin were determined. Anthropometric data
was also collected.
In all patients, Ox-LDL correlated positively with BMI, total cholesterol, LDLc, triglycerides (TG), CRP, glucose, insulin and
HOMAIR; while inversely with TB and HDLc/Total cholesterol ratio (P < 0.05 for all). In multiple linear regression analysis,
LDLc, TG, HDLc and TB levels were significantly associated with Ox-LDL (standardized Beta: 0.656, 0.293, −0.283, −0.164,
respectively; P < 0.01 for all). After removing TG and HDLc from the analysis, HOMAIR was included in the regression
model. In this new model, LDLc remained the best predictor of Ox-LDL levels (β = 0.665, P < 0.001), followed by TB
(β = −0.202, P = 0.002) and HOMAIR (β = 0.163, P = 0.010).
Conclusions: Lower bilirubin levels may contribute to increased LDL oxidation in obese children and adolescents,
predisposing to increased cardiovascular risk.
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Introduction
Bilirubin has important antioxidant and anti-inflammatory
properties. Actually, bilirubin can protect low-density lipo-
protein (LDL) from oxidation [1] and persons expressing
Gilbert syndrome (i.e., unconjugated hyperbilirubinemia)
present lower circulating levels of oxidized-LDL (Ox-LDL)
[2]. Stojanov et al. [3] reported that healthy young men (18
to 22 years old) with high total bilirubin (TB) have lower
concentration of Ox-LDL. Furthermore, a protective asso-
ciation between serum bilirubin level and cardiovascular
disease (CVD) and death exists in both men and women
[4]. Besides, serum bilirubin levels were inversely associated* Correspondence: luisbelo@ff.up.pt
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unless otherwise stated.with body mass index (BMI) values in adults [5], and in a
study involving American children and adolescents, biliru-
bin concentrations were found to be inversely associated
with metabolic syndrome, which seemed to be related to
the insulin resistance (IR) status [6].
Obese children and adolescents already present with
altered CVD risk markers, namely higher IR, triglycerides
(TG), LDL cholesterol (LDLc) and C-reactive protein
(CRP) concentrations and lower high-density lipoprotein
cholesterol (HDLc) and adiponectin levels compared to
controls [7]. It was also reported that Ox-LDL level is
higher in overweight/obese adolescents (compared to lean
adolescents) and that obesity and IR are main independent
predictors of higher Ox-LDL [8,9]. However, the associ-
ation of bilirubin with Ox-LDL levels in young obese
patients is unknown.
The aim of our study is to evaluate the association of
Ox-LDL with clinical data of young obese patients andntral. This is an Open Access article distributed under the terms of the Creative
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lipid profile, and markers of glucose metabolism.
Methods and procedures
Subjects
Obese children and adolescents, aged 11–18 years, were
identified from medical records, at the outpatient clinics
of pediatric obesity in two hospitals in Oporto - Portugal.
A group of children from 5 primary and 2 middle and
high public schools from Oporto suburban setting were
also recruited to this study, enlarging the obese group.
The study protocol was approved by the Committee on
Ethics of both Hospitals and by the Review Committee of
the Scientific Board of the Faculty of Sport of the University
of Oporto.
A total of 125 obese children and adolescents partici-
pated in the study after informed and written consent of
their parents. Smokers, subjects with endocrine disorders,
inflammatory, hepatic or infectious diseases or under any
therapy that could interfere with our results were excluded
from the study.
Procedures and assays
Anthropometric characterization and clinical evaluation
All participants were subjected to clinical examination.
Height and weight were measured. Obesity was defined
as body mass index (BMI) z-score greater than +1.65 for
age and gender, according to 2000 Centre for Disease
Control and Prevention (CDC) growth charts. Waist cir-
cumference was measured at the superior border of the
iliac crest, according to the protocol of the NHANES
[10]. Waist-to-Height ratio (WtHr) was calculated and a
value greater than 0.5 was considered as predictor of
cardiometabolic risk.
Blood samples
Blood was collected by venipuncture in EDTA contain-
ing tubes, after overnight fasting (10-12 h) and processed
within 2 h of collection. Aliquots of plasma were made,
and immediately stored at −80 °C until assayed.
Plasma analysis
Plasma levels of CRP were determined by immunoturbidi-
metry [CRP (latex) High-Sensitivity, Roche Diagnostics]
and quantification of TB was performed by a colorimetric
test (diazotized sulfanilic acid reaction, Roche Diagnos-
tics). Adiponectin plasmatic concentration was evaluated
by using a standard commercial enzyme-linked immuno-
assay (Bender MedSystems, San Diego, CA, USA).
The determination of circulating levels of glucose and
insulin was performed by using routine automated tech-
nology (ABX Diagnostics). Homeostasis model assess-
ment of insulin resistance (HOMAIR) was calculated
according to Matthews [11].The lipid profile was performed in an autoanalyzer
(Cobas Mira S, Roche, Basel, Switzerland), using commer-
cially available kits; total cholesterol and TG concentra-
tions were determined by enzymatic colorimetric tests
(cholesterol oxidase-phenol aminophenazone and glycerol-
3-phosphate oxidase-phenol aminophenazone methods,
Roche, resp.); HDLc was measured using enzymatic colori-
metric test, after selective separation of HDLc fraction (dir-
ect HDL cholesterol, Roche); LDLc was calculated using
Friedewald formula [12]; Ox-LDL was measured directly
in plasma by using a two-site enzyme immunoassay
(oxidized LDL ELISA, Mercodia, Uppsala, Sweden).
Statistical analysis
The distributions of continuous variables were analyzed
using Kolmogorov-Smirnov tests to assess significant
departures from Normality. Normally distributed vari-
ables are presented as mean ± SD (standard deviation)
and those non-normally distributed are presented as
median (interquartile range). Comparisons between
two groups were performed using Student’s unpaired t-
test or Mann–Whitney U test. The association between
categorical variables was analyzed using chi-squared
test and Fisher’s exact test.
The strength of the association between the variables
was estimated by Pearson correlation coefficient, after
log transformation of the variables (whenever necessary).
To evaluate the contribution of the different variables
(clinical and biochemical) to Ox-LDL levels, multiple re-
gression analysis was performed, using stepwise selec-
tion, with an entry criteria of P <0.05. Age, sex, Tanner
stage, weight, BMI, BMI z-score, waist circumference,
WtHr, TG, total cholesterol, LDLc, HDLc, glucose, insu-
lin, HOMAIR, CRP, adiponectin and TB were included
in the analysis as independent variables.
Statistical analysis was performed using the Statistical
Package for Social Sciences (SPSS, version 21.0) for
Windows (SPSS Inc., Armonk, NY, USA). Statistical sig-
nificance was accepted at P less than 0.05.
Results
The mean age of the participants was 13.4 years old, and
only a minority was pre-pubertal (7.2%). The clinical and
analytical data of the whole obese group, and according to
Ox-LDL levels, are presented in Table 1. The obese patients
were divided in two groups on the basis of their Ox-LDL
level, using the cut-off of 39.2 U/l, which corresponds to
the median value for the entire group. The two groups were
matched for age, gender, and number of pre-pubertal par-
ticipants. The group with higher Ox-LDL (equal or higher
than 39.2 U/l) presented significantly higher BMI values,
higher levels of TG, total cholesterol, LDLc, and CRP, and
significantly lower values of TB and HDLc/Total choles-
terol ratio (Table 1). BMI z-score, waist circumference and
Table 1 Anthropometric, nutritional and biochemical variables for total obese patients, and according to oxidized-LDL
(Ox-LDL) levels (lower or higher than the median value observed for total patients, 39.2 U/l)
All obese patients Ox-LDL < 39.2 U/l Ox-LDL ≥ 39.2 U/l
(n = 125) (n = 62) (n = 63) Pa
Age (years) 13.4 ± 1.9 13.3 ± 1.8 13.6 ± 1.9 0.351
Sex (females (%)) 67 (53.6) 35 (56.5) 32 (50.8) 0.592
Tanner (pre-pub (%)) 9 (7.2) 4 (6.5) 5 (7.9) 1.000
Height (cm) 161.8 ± 9.0 162.4 ± 9.2 161.3 ± 8.8 0.490
Weight (Kg) 89.3 ± 22.4 86.7 ± 18.9 91.9 ± 25.3 0.196
BMI (kg/m2) 33.7 ± 6.2 32.6 ± 4.9 34.9 ± 7.1 0.041
BMI z-score 2.28 ± 0.32 2.24 ± 0.29 2.32 ± 0.36 0.150
Waist circumference (cm) 104.9 ± 15.2 103.7 ± 13.3 105.9 ± 16.8 0.420
WtHr 0.65 ± 0.08 0.64 ± 0.07 0.66 ± 0.09 0.227
TG (mg/dl) 89.0 (60.0-119.5) 66.0 (53.0-98.0) 108.0 (85.0-135.0) <0.001
Total cholesterol (mg/dl) 150.0 (133.0-173.5) 135.5 (117.8-155.3) 163.0 (149.0-187.0) <0.001
HDLc (mg/dl) 40.0 (36.0-48.0) 41.0 (37.0-49.3) 40.0 (35.0-46.0) 0.119
LDLc (mg/dl) 89.0 (73.5-107.5) 76.0 (65.0-87.3) 105.0 (90.0-121.0) <0.001
HDLc/Total cholesterol 0.28 (0.24-0.33) 0.33 (0.29-0.36) 0.24 (0.21-0.26) <0.001
Ox-LDL (U/l) 39.2 (32.5-47.6) 32.5 (28.5-36.4) 47.5 (42.9-53.3)
Glucose (mg/dl) 79.0 (74.0-85.5) 78.0 (73.8-84.3) 80.0 (74.0-86.0) 0.233
Insulin (μU/ml) 18.6 (13.8-26.9) 17.7 (13.1-23.4) 21.3 (14.4-29.6) 0.149
HOMAIR 3.58 (2.63-5.52) 3.27 (2.56-4.47) 3.91 (2.64-6.36) 0.106
CRP (mg/l) 1.83 (0.88-4.48) 1.33 (0.66-3.58) 2.86 (1.04-5.03) 0.004
Adiponectin (μg/ml) 5.14 (3.59-7.04) 4.77 (3.38-7.02) 5.28 (3.91-7.12) 0.174
Total bilirubin (μmol/l) 10.60 (9.06-15.39) 11.97 (9.92-18.47) 9.92 (7.18-14.02) 0.001
Results are presented mean ± standard deviation or median (interquartile range), unless otherwise indicated.
Pre-pub, pre-pubertal; BMI, body mass index; WtHr, Waist-to-Height ratio; TG, triglycerides; HDLc, high-density lipoprotein-cholesterol; LDLc, low-density
lipoprotein-cholesterol; VLDLc, very low-density lipoprotein-cholesterol; Ox-LDL, oxidized low-density lipoprotein; HOMAIR, homeostasis model assessment insulin
resistance; CRP, C-reactive protein.
aLower Ox-LDL group versus higher Ox-LDL group.
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LDL, but results did not achieve statistical significance.
No statistically significant differences were found for
metabolic health markers between clinical and school-
based samples (data not shown).
In all patients, Ox-LDL correlated positively and signifi-
cantly with BMI (r = 0.197, P = 0.027), total cholesterol (r =
0.630, P < 0.001), LDLc (r = 0.678, P < 0.001), TG (r = 0.510,
P < 0.001), CRP (r = 0.224, P = 0.012), glucose (r = 0.196,
P = 0.029), insulin (r = 0.186, P = 0.038) and HOMAIR (r =
0.209, P = 0.019); moreover, Ox-LDL levels correlated in-
versely and significantly with TB (r = −0.252, P = 0.005) and
HDLc/Total cholesterol ratio (r = −0.732, P < 0.001).
In multiple linear regression analysis, LDLc, TG, HDLc
and TB levels were statistically associated with Ox-LDL
values (Table 2, model 1). Because the associations with
TG and HDLc were highly expected, we re-ran multiple
linear regression analysis, after exclusion of these two
variables (LDLc was kept in the analysis since is the sub-
strate for oxLDL). In this new analysis, LDLc remainedthe best predictor of Ox-LDL levels, followed by biliru-
bin and HOMAIR (Table 2, model 2).
Discussion
As far as we know this is the first study demonstrating
an association of bilirubin with Ox-LDL levels in young
obese patients.
The strong positive correlations found between Ox-
LDL and both LDLc and TG (with their inclusion in the
regression model of Ox-LDL) are in accordance with lit-
erature. Ox-LDL level is likely to increase with the num-
ber of LDL particles, and high levels of TG lead to the
formation of smaller, denser LDL species, which are
known to be more prone to oxidative modification
[13,14]. On the other hand, HDL is known as an athero-
protective protein and is capable to protect LDL from
oxidative modification in vitro [15,16]. This is in agree-
ment with the inclusion of HDL in our regression ana-
lysis of Ox-LDL (β = −0.283, P < 0.001). Bilirubin was
also an independent predictor of Ox-LDL levels (Table 2,
Table 2 Main determinants of oxidized LDL (Ox-LDL) levels by multiple linear regression analysis
Dependent variable Model Unstandardized Coefficients Standardized Coefficients t P
B Std. Error Beta
Model 1 (R2 = 0.672)
Ln Ox-LDL (Constant) 1.598 0.300 5.322 <0.001
Ln LDLc 0.624 0.054 0.656 11.582 <0.001
Ln TG 0.152 0.029 0.293 5.300 <0.001
Ln HDLc −0.318 0.061 −0.283 −5.212 <0.001
Ln Bilirubin −0.091 0.030 −0.164 −3.100 0.002
Model 2 (R2 = 0.524)*
Ln Ox-LDL (Constant) 1.006 0.286 3.522 0.001
Ln LDLc 0.632 0.059 0.665 10.719 <0.001
Ln Bilirubin −0.113 0.035 −0.202 −3.231 0.002
Ln HOMAIR 0.077 0.029 0.163 2.608 0.010
HDLc, high-density lipoprotein-cholesterol; LDLc, low-density lipoprotein-cholesterol; TG, triglycerides; HOMAIR, homeostasis model assessment insulin resistance.
*Re-ran of multiple linear regression analysis, after exclusion of two variables (TG and HDLc).
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bilirubin is also capable to prevent LDL from oxidation
in vitro [1] and two recent studies involving young males
[3] and patients under hemodialysis [17] reported a simi-
lar association in vivo between bilirubin and Ox-LDL,
suggesting a potential cardiovascular risk protection of
bilirubin.
In children, Ox-LDL was found to associate with adi-
posity and, independently of body fatness, with IR [18].
Indeed, previous reports have demonstrated that obesity
and IR are main independent predictors of higher Ox-
LDL [8,9]. Ryder et al. [9] reported that IR is an inde-
pendent predictor of Ox-LDL when whole-body insulin
sensitivity index is used, but not when HOMAIR is used.
Another study found that Ox-LDL is significantly corre-
lated with fasting insulin and HOMAIR, but these rela-
tionships disappeared after adjustment for BMI [8]. In
the present study, BMI and markers of glucose metabol-
ism were positively and significantly correlated with Ox-
LDL levels. However, only after removing TG and HDLc
from the analysis, HOMAIR was included in the regression
model (model 2; Table 2). In this new model, bilirubin was
the second best predictor of Ox-LDL levels (β = −0.202,
P = 0.002), after LDLc (kept in the analysis) and followed
by HOMAIR (β = 0.163, P = 0.010), explaining approxi-
mately 52% of the variance. It is noteworthy that none
adiposity marker entered this new model, probably due to
adjustment for glucose metabolism markers. Indeed, both
insulin and HOMAIR were highly statistically positively
correlated with adiposity markers, namely with BMI, BMI
z-score, waist circumference and WtHr (r > 0.420, P <
0.001 for all).
In the present study, bilirubin was included in both re-
gression models, independently of confounders. These re-
sults suggest that the antioxidant and/or anti-inflammatoryproperties of bilirubin may explain per se its negative asso-
ciation with Ox-LDL. However, it is also possible that
other antioxidant compounds may contribute to this asso-
ciation. That is, bilirubin levels may actually be a marker of
the status of the antioxidant system. Besides bilirubin, the
endogenous antioxidant system includes other compounds
that have a role in the protection from the deleterious
effects of oxygen free radicals.
A previous work from our group demonstrated that
young obese patients with higher body fat percentage
present lower circulating levels of bilirubin and a higher
degree of inflammation [19]. In the present study we did
not assess body composition (due to logistic reasons) and
the only anthropometric marker related with Ox-LDL was
BMI. However, it would be interesting to investigate if
body fat mass in obese patients relates concomitantly with
bilirubin and Ox-LDL. Furthermore, in the present study,
the lack of a significant association between waist circum-
ference and Ox-LDL levels contrast with previous findings
in lean and overweight/obese adolescents [9] and may in-
dicate that this is not a consistent or sensitive predictor of
Ox-LDL amongst different youth populations. Small inter-
individual differences in this measurement (performed at
different institutions and only in obese patients) may have
contributed to the absence of the association but are un-
likely to explain this result by itself. Indeed, the correlation
between waist circumference and Ox-LDL was far from
being statistically significant. In addition, waist circumfer-
ence presented well known correlations with other
variables, such as insulin, HOMAIR, TG and HDLc (all
statistically significant; data not shown).
Adiponectin is an important antidiabetic and anti-
atherogenic adipokine. In obese children and adoles-
cents, adiponectin levels are inversely and significantly
correlated with BMI, TG, and HDLc/Total cholesterol,
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[20]. In the present study we found no significant
association between adiponectin and Ox-LDL levels, not
suggesting a major role of this adipokine in regulating
Ox-LDL level in young obese patients.
In conclusion, TB is independently and negatively asso-
ciated with OX-LDL levels in young obese patients. Thus,
patients presenting lower bilirubin may be at increased
atherogenic risk and strategies to reduce Ox-LDL levels
should be seek early in life.
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